BIO Panel: Polymerase, Protease Inhibitor Combinations On The Horizon For Hepatitis C
This article was originally published in The Pink Sheet Daily
Executive Summary
Proof of concept study evaluating polymerase/protease inhibitor combinations for HCV could start within the next year, Vertex predicts.
You may also be interested in...
Novartis/Idenix Report Mixed Interim Data For Hep C Candidate Valopicitabine
Idenix will await full 72-week data and data from another combination study before deciding the fate of the HCV therapy.
Novartis/Idenix Report Mixed Interim Data For Hep C Candidate Valopicitabine
Idenix will await full 72-week data and data from another combination study before deciding the fate of the HCV therapy.
Vertex Hopes To PROVE Telaprevir’s Promise With Final Installment Of Phase II Program
Company plans to begin Phase III in the second half of 2007; further protocol discussions with FDA are planned for mid-2007.